Skip to main content

Advertisement

Table 1 Summary of design and outcomes of trials investigating the role of treatment for herpes simplex virus type 2 (HSV-2) for HIV prevention

From: Investing in the future: lessons learnt from communicating the results of HSV/ HIV intervention trials in South Africa

Author Study design & population Intervention Expected Outcome
Trials of HSV-2 suppressive therapy
Celum et al., 2008 Randomised, double blind, placebo-controlled trial in 3172 HIV-negative, HSV-2–positive participants (1358 women, 1814 men who have sex with men) Acyclovir, 400 mg twice daily, for 12–18 months Prevention of HIV acquisition
Delany et al., 2009 Randomized, double-blind, placebo-controlled trial in 299 HIV-positive, HSV-2–positive women with CD4 > 250 not on HAART in South Africa Acyclovir, 400 mg twice daily, for 3 months Reduction of HIV infectiousness
Celum et al., 2009 Randomised, double blind, placebo-controlled trial in 3408 HIV-1 / HSV-2 dually-infected persons within HIV-1 serodiscordant Couples Acyclovir, 400 mg twice daily, for 12-24 months Prevention of HIV transmission and disease progression
Trials of HSV-2 episodic therapy
Paz-Bailey et al., 2009 Randomised, double blind, placebo-controlled trial in 615 men with genital ulcer disease Acyclovir 400mg three times a day, for 5 days Reduction of HIV infectiousness Increased ulcer healing